What's Going On With Cue Biopharma Shares Tuesday?

Zinger Key Points

Cue Biopharma, Inc. CUE shares are trading lower on Tuesday. The company reported 2024 fiscal-year earnings on Monday after the market closed.

What To Know: The company reported collaboration revenue of $9.3 million for 2024, compared to $5.5 million for 2023. It said the increase in revenue was due to its strategic collaboration with Ono Pharmaceutical.

It reported research and development expenses of $36.3 million, down from $40.8 million for the prior year. Cue attributed the decrease to lower clinical trial costs and employee compensation.

The company ended the year with $22.5 million in cash and cash equivalents.

Daniel Passeri, CEO of Cue Biopharma, said, “During 2024 and Q1 2025, we made significant progress shaping the company for success. We believe that the ongoing advancement of our prioritized autoimmune programs and the implementation of a highly focused strategic business model, support our ability to exploit the potentially disruptive opportunity of our Immuno-STAT™ platform, specifically CUE-401.”

See Also: Axsome’s Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder

CUE Price Action: At the time of publication, Cue shares are trading 12.2% lower at 80 cents, according to data from Benzinga Pro.

Image: via Shutterstock

CUE Logo
CUECue Biopharma Inc
$0.85662.43%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
10.05
Growth
-
Quality
-
Value
56.45
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech firms could benefit from CUE's decline?
How might Ono Pharmaceutical leverage its partnership?
Are there investors looking for undervalued biotech stocks?
Which autoimmune treatments are gaining traction in the market?
What impact will CUE-401 have on competitive positioning?
Which companies are exploring similar platforms to Immuno-STAT™?
How will decreased R&D expenses affect investor confidence?
What trends are emerging in clinical trials post-Cue's report?
Which cash-rich biotech firms are likely to acquire CUE?
Could Cue Biopharma's challenges lead to merger opportunities?
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...